Trevi Therapeutics (TRVI) Enterprise Value (2019 - 2026)

Trevi Therapeutics' Enterprise Value history runs 9 years deep, the most recent figure standing at -$171.8 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 66.36% year-over-year to -$171.8 million; the TTM figure through Mar 2026 stood at -$171.8 million (down 66.36% YoY), while the FY2025 annual figure was -$188.3 million, down 74.93% from the prior year.
• Enterprise Value for Q1 2026 stood at -$171.8 million, up from -$188.3 million in the prior quarter.
• The five-year high for Enterprise Value was -$42.3 million in Q1 2022, with the low at -$203.9 million in Q2 2025.
• The 5-year median for Enterprise Value is -$103.3 million (2025), against an average of -$113.0 million.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value sank 328.42% in 2022, then soared 34.55% in 2024.
• Trevi Therapeutics' Enterprise Value stood at -$120.5 million in 2022, then jumped by 31.15% to -$83.0 million in 2023, then declined by 29.71% to -$107.6 million in 2024, then tumbled by 74.93% to -$188.3 million in 2025, then climbed by 8.75% to -$171.8 million in 2026.
• Business Quant data shows TRVI's Enterprise Value at -$171.8 million in Q1 2026, -$188.3 million in Q4 2025, and -$194.9 million in Q3 2025.